Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Comment by fairweather1on Aug 05, 2014 7:02am
191 Views
Post# 22808784

RE:RE:RE:dumb question

RE:RE:RE:dumb question
read any of the recent quarterlies and this point is discussed.  I am trying to get a bit of clarification on some of these points from mgt, but they aren't too communicative right now.  I guess we will have to wait until aug 7 for an update.  Each succeeding quarter's forecast of closure costs should be closer to reality.

I think a big factor is the relationship with Ford that might allow transition of "some" staff without severance. 

At this point, I am actually more interested in how they are managing staff for the final quarters given the uncertainties surrounding the whole affair.  A lot of investors are expecting profits to continue at the same level to the end.  This would be challenging, though not impossible.  I think the share price shows some skepticism of a clean windup...hopefully the market is wrong and hopefully there is a takeover on the horizon.
Bullboard Posts